New Delhi: The U.S. Food and Drug Administration (USFDA) has approved expanded use of MannKind's inhaled rapid-acting insulin in children with diabetes, offering patients under 18 years of age a needle-free treatment option, the company said on Friday.
USFDA Approves MannKind's Inhaled Insulin Afrezza for Children with Diabetes
Written By : sheeba farhat
Published On 2026-05-31 05:30 GMT | Update On 2026-05-31 05:30 GMT
The approval broadens treatment options for younger patients who require insulin, often several times a day, to manage diabetes, a condition where the body cannot properly regulate blood sugar levels.
According to Jennifer Segrist, mother of 15-year-old Taisie Segrist, who was part of MannKind's research study, her daughter initially needed several injections a day, which was traumatizing for a child her age.
But switching to inhaled insulin had been "life changing," making her more independent in managing the condition, Segrist told Reuters.
"It really does make a huge difference… diabetes is not such a huge weight on her shoulders anymore."
Unlike conventional insulin, which is injected subcutaneously and could affect adherence especially in children, MannKind's Afrezza is inhaled through a small device to help control blood sugar levels at mealtimes.
It was first approved by the FDA for adults in June 2014.
The drug, approved for use in children aged six and above with Type 1 and Type 2 diabetes, has a rapid onset and short duration of action, more closely mimicking the body's natural insulin response to meals. The company said eligible patients can access Afrezza for $35 or less a month.
However, the company said Afrezza could cause serious side effects such as sudden lung problems.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.